It is reported that HDAC inhibitors are capable of downregulating DNA repair induced genes of the HR pathway in cells within certain tumors (Konstantinopoulos et al., 2014[20]), a logical rationale for the use of HDAC inhibitors in cancer therapy. Here, HDAC9 is linked to cancer.